Patents Examined by Layla Soroush
  • Intranasal spray device containing pharmaceutical composition
    Patent number: 9814705
    Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Depomed, Inc.
    Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
  • Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
    Patent number: 9815844
    Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 14, 2017
    Assignee: KemPharm, Inc.
    Inventors: Brian W. Heinrich, Da-Ming Gou, Mahmoud Mirmehrabi, Bernhard Paul, Daniel James Coughlin
  • Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
    Patent number: 9814728
    Abstract: The use of BETi as a potential treatment for FSHD is provided. Specifically, the use of BETi, and particularly selective BETi for BRD4, are shown to inhibit DUX4 expression which is expected to result in a decrease in the severity of symptoms of FSHD. Further, the treatments are shown to work when pulsed as opposed to continuous. This allows for a BETi to be supplied to a human in a pulse, and then allows the human to not need any additional treatment for a window at least as long as the one of the treatment pulse.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: November 14, 2017
    Assignee: Saint Louis University
    Inventors: Francis M. Sverdrup, Stephen J. Tapscott
  • Combination of a centrally-acting analgesic and a selective cyclooxygenase-2 inhibitor anti-inflammatory agent for the treatment of inflammation and pain in the veterinary field
    Patent number: 9808433
    Abstract: The present invention relates to veterinary pharmaceutical compositions for the treatment of pain and inflammation, containing a combination of Tramadol and Firocoxib, for oral administration.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: November 7, 2017
    Assignee: FORMEVET S.R.L.
    Inventors: Andrea Formenti, Filippo Formenti
  • Phenylephrine-containing liquid formulations
    Patent number: 9801941
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 31, 2017
    Assignee: Wyeth LLC
    Inventors: Amanda Alley, William Bubnis, Stephanie Shield
  • Tetrasubstituted alkene compounds and their use
    Patent number: 9796683
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 24, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
  • Antimicrobial compositions and related methods
    Patent number: 9750755
    Abstract: A liquid antimicrobial composition comprising an organic acid and one or more anionic surfactants is disclosed. In one embodiment, the organic acid is lactic acid and the anionic surfactant is sodium octane sulfonate. In a preferred embodiment, the antimicrobial solution is formulated as a teat dip for lactating animals, particularly cows. In other embodiments, the antimicrobial compositions may be used in personal care, hard surface care including hard surface disinfection in households, food processing, hospitals, restaurants, hotels, showers, or topically as hand soaps, surgical scrubs, and hoof disease mitigators.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: September 5, 2017
    Assignee: DeLaval Holding AB
    Inventors: Fahim U. Ahmed, Alex Skender, Chris Foret, Thomas C. Hemling, N. Camelia Traistaru
  • Compositions and methods for enhancing brain function
    Patent number: 9737519
    Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: August 22, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Compositions and methods for enhancing brain function
    Patent number: 9737580
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: August 22, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Compositions of tolperisone
    Patent number: 9675598
    Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: June 13, 2017
    Assignee: Sanochemia Pharmazeutika AG
    Inventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
  • Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
    Patent number: 9675698
    Abstract: The present invention relates to a pharmaceutical composition in the form of a hydro-alcoholic gel or a solution for transdermal application, comprising: from about 0.2% to about 1.5% of dihydrotestosterone; and from about 0.2 to about 3% of isopropyl myristate.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: June 13, 2017
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Valerie Masini-Eteve, Brigitte Taravella
  • Methods of administering tolperisone for therapeutic purposes
    Patent number: 9662317
    Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: May 30, 2017
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
  • Pharmaceutical composition
    Patent number: 9655883
    Abstract: A topical composition comprises at least 5-wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, and anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: May 23, 2017
    Assignee: SLA PHARMA AG
    Inventor: David Nigel Armstrong
  • Compositions and methods for suppressing endometrial proliferation
    Patent number: 9616074
    Abstract: The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: April 11, 2017
    Assignee: REPROS THERAPEUTICS INC.
    Inventor: Joseph S. Podolski
  • Compositions and methods for enhancing brain function
    Patent number: 9603884
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: March 28, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
    Patent number: 9561277
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 7, 2017
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
    Patent number: 9555133
    Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: January 31, 2017
    Assignee: AMAG Pharmaceuticals, Inc.
    Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
  • Tyrosine kinase inhibitors as anti-kinetoplastid agents
    Patent number: 9545410
    Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid or apicomplexan protozoan with tyrosine kinase inhibitors.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: January 17, 2017
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Kojo Mensa-Wilmot
  • Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
    Patent number: 9498473
    Abstract: Compositions of hepatic therapeutic actives from one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid compounds. Also, methods for treating various liver diseases or certain cancers with such hepatic therapeutic actives, as well as providing liver health maintenance.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: November 22, 2016
    Assignee: Heptiva LLC
    Inventor: Vincent I. Teow
  • Topical antimicrobial compositions and methods of using same
    Patent number: 9474729
    Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: October 25, 2016
    Assignee: HYDROMER, INC.
    Inventors: Irina Grigorian, Manfred F. Dyck, Rainer Gruening